Effects of calcium antagonists on insulin sensitivity and other metabolic parameters

American Journal of Cardiology

Volumn 79, Issue 10 A, 1997, Pages 24-28

  Sowers, James R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST;

ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; PRIORITY JOURNAL;

EID: 0030785599     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89421-0     Document Type: Conference Paper

References (57)

1. Flack JM, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med. 91:((suppl 1A)):1991;115-205.
2. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens. 6:((suppl.)):1993;260-270.
3. Hypertension. 23:1994;145-158.
4. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med. 123:1994;647-652.
5. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension. 26:1995;869-879.
6. Falkner B, Hulman S, Tannenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. Hypertension. 16:1990;706-711.
7. Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension. 21:1993;129-135.
8. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertensives are related to metabolic risk factors for cardiovascular disease. J Intern Med. 227:1990;273-278.
9. Monolio TA, Savage PJ, Burke GL. Association of fasting insulin with blood pressure and lipids in young adults: the Cardia Study. Atherosclerosis. 10:1990;430-436.
10. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med. 101:((3A)):1996;33S-46S.
11. Sowers JR, Mohanty PK. Comparison of calcium-entry blockers and diuretics in the treatment of hypertensive patients. Circulation. 75:((suppl 5)):1987;V170-V173.
12. Sowers JR. Is hypertension an insulin-resistant state? Metabolic changes associated with hypertension and antihypertensive therapy. Am Heart J. 122:1991;932-935.
13. Sowers JR. Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Nephrol Dial Transplant. 10:((suppl 9)):1995;52-55.
14. Walsh MF, Dominguez LJ, Sowers JR. Metabolic abnormalities in cardiac ischemia. Cardiol Clin. 13:1995;529-538.
15. Standley PR, Safdar A, Bapna C, Sowers JR. Increased platelet cytosolic calcium responses to low density lipoprotein in type II diabetes with and without hypertension. Am J Hypertens. 6:1993;938-943.
16. Aviram M. Modified forms of low density lipoprotein affect platelet aggregation in vitro. Thomb Res. 53:1989;561-567.
17. Sowers JR, Raman BB, Afonso LC, Bedford-Rice K, Standley PR. Effects of antihypertensive therapy on platelet cytosolic calcium responses to low density lipoprotein cholesterol. J Hum Hypertens. 10:1996;177-180.
18. Sowers JR. The impact of diuretics on potassium and glucose. J Cardiovasc Pharmacol. 6:1984;5477-5482.
19. Weinberger MH. Antihypertensive therapy and lipids. Arch Intern Med. 145:1985;1102-1105.
20. Berglund G, Anderson O, Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide. Acta Med Scand. 220:1986;419-424.
21. Samuel P, Kirkendall W, Shaefer EJ, Chin B. Effects of isradipine, a new calcium antagonist, versus hydrochlorothiazide on serum lipids and apolipoproteins in patients with systemic hypertension. Am J Cardiol. 62:1988;1068-1071.
22. Lardinois CK, Neumann SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 148:1988;1280-1288.
23. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 321:1989;868-873.
24. Kaplan NM. Effects of antihypertensive therapy on insulin resistance. Hypertension. 19:1992;116-118.
25. Holland OB, Pool PE. Metabolic changes with antihypertensive therapy of the salt-sensitive patient. Am J Cardiol. 61:1988;53-59.
26. Ramsey LE, Yeo WW, Jackson PR. Influence of diuretics, calcium antagonists, and α -blockers on insulin sensitivity and glucose tolerance in hypertensive patients. J Cardiovasc Pharmacol. 20:1992;S49-S54.
27. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274:1995;620-625.
28. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
29. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond G. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA. 276:1996;785-791.
30. Epstein M. Calcium antagonists: still appropriate as first line antihypertensive agents. Am J Hypertens. 9:1996;110-121.
31. Epstein M. The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk. Am J Cardiol. 79:((suppl 10A)):1997;9-19.
32. Messerli FH. Case control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med. 123:1995;888-889.
33. Borhani NO, Bond G, Sowers JR. The multicenter isradipine/diuretic atherosclerotic study: a study of the antiatherogenic properties of isradipine in hypertensive patients. J Cardiovasc Pharmacol. 18:1991;15-19.
34. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M. . Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol. 77:1996;713-722.
35. Sanatoro D, Natali A, Palombo C. Effects of chronic angiotensin converting inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension. 20:1992;181-191.
36. Giugliano D, DeRosa N, Marfella R. Comparison of nitrendipine and cilazapril in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens. 6:1993;927-932.
37. Sheu WH, Swislocki ALM, Hoffman B, Chen DI, Reaven GM. Comparison of the effects of atenolol and nifedipine on glucose, insulin and lipid metabolism in patients with hypertension. Am J Hypertens. 4:1991;199-205.
38. Ferrari P, Giachino D, Weidmann P. Unaltered insulin sensitivity during calcium channel blockage with amlodipine. J Clin Pharmacol. 41:1991;109-113.
39. Ferrara LA, Panzarasa R, Pasanisi F, Mancini M, Zanchetti A. The antihypertensive and metabolic effects of nicardipine in non-insulin-dependent diabetes with hypertension. The NIDDM study. High Blood Press. 2:1993;37-44.
40. Zenetti-Elshater F, Pingitore R, Beretta-Piccoli C, Riesen W, Heinen G. Calcium antagonists for treatment of diabetes associated hypertension. Metabolic and renal effects of amlodipine. Am J Hypertens. 7:1994;36-45.
41. Morris AD, Donnelly R, Connell J, Reed JL. Effects of the calcium antagonist lacidipine on insulin sensitivity in essential hypertension. Horm Metab Res. 26:1994;257-259.
42. Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens. 7:1989;551-559.
43. Ferrari P, Rosman J, Weiderman P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol. 67:1991;26-35.
44. Lasseter KC, Muller FO, Garrett BN, Marazzi P, Fodor JG. Pharmacokinetics, pharmacodynamics, and clinical utility of nisoldipine coat core in the treatment of essential hypertension. January 1996. Clinical Pharma Association, Miami, Florida.
45. Odigwe CO, McCulloch AJ, Williams DO, Tunbridge WMG. A trial of the calcium antagonist nisoldipine in hypertensive non-insulin-dependent diabetic patients. Diabet Med. 3:1986;463-467.
46. Clarke CWF, Kubil MM. Nifedipine and nisoldipine in hypertensive diabetics. J Hum Hypertens. 5:191;517-522.
47. Winocour PD, Halushla PV, Colwell JA. The platelets: physiology and pharmacology. Longnecker GL. Platelet. 1985;341-366 Academic Press, New York.
48. Knorr M, Locher R, Vogt E. Rapid activation of human platelets by low concentrations of low-density lipoprotein via the phosphoinositol cycle. Eur J Biochem. 172:1988;753-759.
49. Sachinidia A, Locker R, Mengden T, Vitter W. Low-density lipoprotein elevates intracellular calcium and pH in vascular smooth muscle cells and fibroblasts without mediation of LDL receptor. Biochem Biophys Res Commun. 167:1990;353-358.
50. Hassal DG, Forrect LA, Bruckdorfer KP. Influence of plasma lipoproteins on platelet aggregation in a normal male population. Arteriosclerosis. 3:1983;332-338.
51. Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med. 290:1974;434-438.
52. Joist JH, Baker RK, Schonfeld G. Increased in vivo and in vitro platelet function in type II and type IV hyperlipoproteinemia. Thromb Res. 15:1979;95-100.
53. Sowers JR, Zemel MB, Standley PR. Calcium and hypertension. J Lab Clin Med. 114:1989;338-348.
54. Ram JL, Standley PR, Sowers JR. Calcium function in vascular smooth muscle and its relationship to hypertension. Epstein M, Loutzenhiser R. Calcium Antagonists in Clinical Medicine. 1992;29-48 Hanley and Belfus, St. Louis.
55. Standley PR, Bakir MH, Sowers JR. Vascular insulin abnormalities, hypertension and accelerated atherosclerosis. Am J Kidney Dis. 21:1993;39-46.
56. Levy J, Gavin JR III, Sowers JR. Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med. 96:1994;260-273.
57. Davis BR, Cutler JA, Gordon DJ, Furberg DC, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 9:1996;342-360.